Evidence map›Paper›PMID 26946489›Full record

Trial reportNeurogastroenterology and motility2016

Baseline features and differences in 48 week clinical outcomes in patients with gastroparesis and type 1 vs type 2 diabetes.

K L Koch, W L Hasler, K P Yates, H P Parkman, P J Pasricha, J Calles-Escandon, W J Snape, T L Abell, R W McCallum, L A Nguyen and 7 more

Open access · bronzeAbstract readClinical TrialComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Neurogastroenterology and motility, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
7.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 58 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Reconsideration of the Gastroparetic Syndrome.Current gastroenterology reports · 2023
    Review
  10. Article
  11. Progress in Gastroparesis - A Narrative Review of the Work of the Gastroparesis Clinical Research Consortium.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2022
    Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 11 institutions in 1 country.

K L KochSection on Gastroenterology, Wake Forest University, Winston-Salem, NC, USA.
W L HaslerDivision of Gastroenterology, University of Michigan, Ann Arbor, MI, USA.
K P YatesJohns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA.
H P ParkmanSection of Gastroenterology, Temple University, Philadelphia, PA, USA.
P J PasrichaCenter for Neurogastroenterology, Johns Hopkins Bayview Medical Center, Baltimore, MD, USA.
J Calles-EscandonEndocrinology Section, MetroHealth Medical Center, Cleveland, OH, USA.
W J SnapeCalifornia Pacific Medical Center, San Francisco, CA, USA.
T L AbellDigestive and Liver Health, University of Louisville, Louisville, KY, USA.
R W McCallumDivision of Gastroenterology, Texas Tech University, El Paso, TX, USA.
L A NguyenDivision of Gastroenterology, Stanford University, Palo Alto, CA, USA.
I SarosiekDivision of Gastroenterology, Texas Tech University, El Paso, TX, USA.
G FarrugiaDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
J TonasciaJohns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA.
L LeeJohns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA.
L MirielJohns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA.
F HamiltonNational Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, USA.
NIDDK Gastroparesis Clinical Research Consortium (GpCRC)
Johns Hopkins University · USTexas Tech University · USCalifornia Pacific Medical Center · USMayo Clinic in Arizona · USMetroHealth Medical Center · USNational Institute of Diabetes and Digestive and Kidney Diseases · USStanford University · USTemple University · USUniversity of Louisville · USUniversity of Michigan–Ann Arbor · USWake Forest University · US

Funding

Gastroparesis Consortium Continuation-Data Coordinating CenterU01DK074008 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI TONASCIA, JAMES A · 2006 to 2015
$17.4M
Subtypes of GastroparesisU01DK073974 · NIDDK · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Baharak Moshiree · 2006 to 2026
$7.4M
Temple University Gastroparesis Clinical CenterU01DK073975 · NIDDK · TEMPLE UNIV OF THE COMMONWEALTH · PI HENRY PAUL PARKMAN · 2006 to 2026
$7.4M
U of L Clinical Center to Investigate the Pathogenesis, Etiology, and Treatment of Gastroparesis through the NIDDK Gastroparesis ConsortiumU01DK074007 · NIDDK · UNIVERSITY OF MISSISSIPPI MED CTR · PI Thomas Lyman Abell · 2006 to 2026
$7.0M
Molecular Approaches to Pathogenesis/Therapy in GastropaU01DK073983 · NIDDK · UNIVERSITY OF TEXAS MED BR GALVESTON · PI PANKAJ J PASRICHA · 2006 to 2026
$6.8M
The GpCRC Pediatric Gastroparesis Registry 2 (PGpR2): Characterization and Clinical Course of Symptoms and Gastric Emptying in Pediatric, Adolescent, and Young Adult Participants with Symptoms of GastU01DK074035 · NIDDK · UNIVERSITY OF KANSAS MEDICAL CENTER · PI Irene Sarosiek · 2008 to 2026
$6.7M
Visceral Afferent Dysfunction in Diabetic GastropathyU01DK073985 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI HASLER, WILLIAM L · 2006 to 2015
$2.7M
NIDDK NIH HHS U01 DK073974NIDDK NIH HHS U01 DK073975NIDDK NIH HHS U01 DK073983NIDDK NIH HHS U01 DK073985NIDDK NIH HHS U01 DK074007NIDDK NIH HHS U01 DK074008NIDDK NIH HHS U01 DK074035
6 · The paper itself

Abstract

backgroundIn studies of diabetic gastroparesis, patients with type 1 and type 2 diabetes mellitus (T1DM, T2DM) are often combined for analyses. We compared gastroparesis severity, healthcare utilization, psychological function, and quality of life in T1DM vs T2DM gastroparesis patients.

methodsQuestionnaire, laboratory, and scintigraphy data from patients with gastroparesis and T1DM and T2DM from seven centers of the National Institute of Diabetes and Digestive and Kidney Diseases Gastroparesis Clinical Research Consortium Registry were compared at enrollment and after 48 weeks. Multiple regression models assessed baseline and follow-up differences between diabetes subtypes. KEY

resultsAt baseline, T1DM patients (N = 78) had slower gastric emptying, more hospitalizations, more gastric stimulator implantations, higher hemoglobin A1c (HbA1c), and more anxiety vs T2DM patients (N = 59). Independent discriminators of patients with T1DM vs T2DM included worse gastroesophageal reflux disease, less bloating, more peripheral neuropathy, and fewer comorbidities (p ≤ 0.05). On follow-up, gastrointestinal (GI) symptom scores decreased only in T2DM (p < 0.05), but not in T1DM patients who reported greater prokinetic, proton pump inhibitor, anxiolytic, and gastric stimulator usage over 48 weeks (p ≤ 0.03). Gastrointestinal symptoms at baseline and 48 weeks with both subtypes were not associated with HbA1c, peripheral neuropathy, psychological factors, or quality of life. CONCLUSIONS & INFERENCES: Baseline symptoms were similar in T1DM and T2DM patients, even though T1DM patients had worse gastric emptying delays and higher HbA1c suggesting other factors mediate symptom severity. Symptom scores at 48 weeks decreased in T2DM, but not T1DM patients, despite increased medical and surgical treatment utilization by T1DM patients. Defining causes of different outcomes in diabetic gastroparesis warrants further investigation.

Indexed as

AdultDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2FemaleFollow-Up StudiesGastroparesisHumansMaleMiddle AgedQuality of LifeRegistriesTreatment Outcomegastric emptyinggastroparesishyperglycemianausea and vomitingtype 1 and type 2 diabetes mellitus

Identifiers

PMID26946489
PMCPMC5319426
OpenAlexW2289703121

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.